Business Wire

Eaton to Showcase Technologies for Hydrogen-Powered Commercial Vehicles at IAA Transportation 2024

10.9.2024 13:30:00 EEST | Business Wire | Press release

Share

Intelligent power management company Eaton announced it will showcase a broad range of innovative solutions for hydrogen-powered commercial vehicles September 17–22 at IAA Transportation 2024 in Hanover, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910157651/en/

Eaton’s hydrogen recirculation blower cycles surplus hydrogen to the stack's inlet, which extends system longevity through anode purging. (Photo: Business Wire)

“Eaton believes that hydrogen can play a significant role in decarbonizing commercial vehicles,” said Scott Adams, senior vice president, Global Products, Eaton’s Mobility Group. “Whether a vehicle is powered by hydrogen fuel cells or a hydrogen internal combustion engine, Eaton’s broad range of innovative solutions makes us a valuable supplier partner.”

Eaton’s TVS technology improves fuel cell performance

Recirculating excess hydrogen through the fuel cell stack is critical for achieving high efficiency in fuel cells. Based on Eaton’s TVS technology, its hydrogen recirculation blower cycles surplus hydrogen to the stack's inlet, extending system longevity through anode purging, managing water, and reducing cold start issues while maximizing hydrogen utilization by improving efficiency and stack responsiveness.

H2 ICE engines need significantly more air for the combustion process. Eaton’s TVS supercharger provides the ability to produce instant air flow at low engine speeds, can be disengaged to reduce parasitic losses when not needed, and can be optimized to complement a turbocharger in super-turbo applications.

Hydrogen ICE solutions present challenges requiring innovative solutions

Hydrogen-powered internal combustion engines pose unique challenges that fall squarely within Eaton’s area of expertise – engine air management.

H2 ICE engines have higher combustion chamber temperatures compared to diesel engines, making them susceptible to surface auto-ignition or knocking. Eaton, one of the largest global producers of engine valves, leveraged its extensive experience to develop its next generation of hollow valves designed specifically for commercial vehicles and hydrogen-powered applications. The innovative design of the new hollow valves results in lower temperatures, which reduces the risk of engine knock and allows the valve to be produced with more cost-effective materials.

Hydrogen internal combustion vehicles require robust engine brakes

H2 ICE engines need more engine braking due to their low compression ratio. Eaton’s 1.5 stroke engine brake delivers 40% more braking power at low speed compared to a conventional engine brake. Testing has shown that the combination of an Eaton supercharger and 1.5-stroke engine brake provides additional braking power of up to 20%.

For more information on Eaton’s commercial vehicle market solutions, visit Hall 21, Booth B22 at IAA Transportation 2024.

Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.

Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit http://www.eaton.com. Follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910157651/en/

Contacts

Thomas Nellenbach
(216) 333-2876 (cell)
thomasjnellenbach@eaton.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye